Clinical Trial Update: Pioglitazone Hydrochloride (Actos(Registered Trademark)) to Treat Asthma [Phase 2]

View source ↗

Summary

A Phase 2 trial of pioglitazone hydrochloride (Actos) for asthma sponsored by NHLBI has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Actos (Pioglitazone)

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Asthma, Airway Inflammation | Phase 2 | Status: WITHDRAWN